SCHEMBL6490761

SCHEMBL6490761

Cc1ccccc1C1CCN(C(=O)C2CCc3c(C)cccc3C(=O)C2)CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 2/20 0.43
KCNH2 Q12809 1/20 0.43
KMT2A Q03164 6/20 0.42
MEN1 O00255 5/20 0.42
TRPV1 Q8NER1 1/20 0.41
MGLL Q99685 1/20 0.41
TSHR P16473 2/20 0.40
FAAH O00519 1/20 0.40
AVPR1A P37288 1/20 0.40
HSD11B1 P28845 1/20 0.39
DRD4 P21917 1/20 0.39
MAPT P10636 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
MCHR1 Q99705 1/20 0.38
HTR7 P34969 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6079726 0.93 KMT2A (0.40) OPRL1KCNH2KMT2AMEN1TRPV1
SCHEMBL6080691 0.92 OPRL1 (0.41) OPRL1KCNH2KMT2AMEN1TRPV1
SCHEMBL6080094 0.92 BACE1 (0.41) OPRL1KCNH2KMT2AMEN1TRPV1
SCHEMBL6076026 0.92 ALDH1A1 (0.40) OPRL1KCNH2KMT2AMEN1TRPV1
SCHEMBL6501862 0.90 BACE1 (0.42) KCNH2KMT2AMEN1TSHRMAPT
SCHEMBL6075438 0.90 KMT2A (0.39) OPRL1KCNH2KMT2AMEN1MGLL
SCHEMBL6075954 0.90 KMT2A (0.53) KMT2AMEN1DRD4MAPTNPSR1
SCHEMBL6075118 0.89 MGLL (0.41) OPRL1KCNH2KMT2AMEN1TRPV1
SCHEMBL6075129 0.89 RBP4 (0.50)
SCHEMBL6075935 0.89 KMT2A (0.40) OPRL1KMT2AMEN1TSHRHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6969724-B2 Compounds SMITHKLINE BEECHAM-SPA (GB) 2005-11-29 US disclosed
US-20040024218-A1 Novel compounds SMITHKLINE BEECHAM SPA 2004-02-05 US disclosed
EP-1129072-A2 N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS Smithkline Beecham S.p.A. (IT) 2001-09-05 EP disclosed
WO-2000027815-A2 N-SUBSTITUTED AZACYCLES, THEIR PREPARATION AND THEIR USE AS ORL-1 RECEPTOR LIGANDS SMITHKLINE BEECHAM SPA (IT) 2000-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024218-A1 Novel compounds OXER1, CLIC1, CCR1 OPRL1 9/4885KCNH2 706/4885KMT2A 3155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.